Market Eyes LiveQuest Diagnostics Inc. (DGX) Stock Rating & Analysis
MELANY's data-driven read on Quest Diagnostics Inc. · Services-Medical Laboratories.
Quest Diagnostics is a leading independent US provider of diagnostic testing, information, and services. More than 97% of revenue comes from clinical testing, anatomic pathology, esoteric testing, and substance abuse testing, with specimens collected through a national network of roughly 2,400 patient service centers as well as many doctors' offices and hospitals. A much smaller diagnostic solutions segment offers clinical trials testing, risk-assessment services, and information technology solutions.
Why DGX scores 64/100
MELANY scores Quest Diagnostics Inc. 64/100 by weighing eight factors. Here is how DGX breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
Margins, returns on capital, and balance-sheet strength.
Direction and relative strength of the recent share-price trend.
- Price +10.5% above 50-day MA
- 50-day MA above 200-day (golden cross zone)
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 4 of last 4 quarters
What Wall Street price targets and revisions are signalling.
- Institutional net buying +33.7%
Near-term events that could move the stock.
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
Key risks for DGX
- Trading near 52-week high, limited upside without new positive catalyst
Sector and theme context
Quest Diagnostics Inc. sits in the Healthcare sector theme, which MELANY currently rates 51/100 for strength. Theme strength feeds DGX's momentum and catalyst factors above.
Tracking DGX
Quest Diagnostics Inc. rates Hold right now, so MELANY is not flagging a fresh entry. Create a free account to add DGX to your watchlist and get alerted the moment the rating changes.
How MELANY rates DGX
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Quest Diagnostics Inc.'s 64/100 reflects mature factor weighting for its profile.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about DGX
Is Quest Diagnostics Inc. (DGX) a buy?
As of 2026-08-24, MELANY rated Quest Diagnostics Inc. Hold with a composite score of 64/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Quest Diagnostics Inc.'s MELANY score?
Quest Diagnostics Inc. (DGX) has a MELANY composite score of 64/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, and macro fit.
How is the DGX stock rating calculated?
MELANY scores DGX from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Quest Diagnostics Inc. stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Quest Diagnostics Inc. (DGX) Hold with a composite of 64/100 as of 2026-08-24. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the DGX stock price forecast?
MELANY does not publish price targets or forecasts for DGX. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 64/100 across eight factors for Quest Diagnostics Inc., and re-scores automatically as new price, earnings, and fundamental data arrive.
Is DGX stock overvalued or undervalued?
MELANY's valuation factor currently reads 52/100 for Quest Diagnostics Inc., where a higher score means the price looks more attractive against earnings, growth, and peers. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives DGX's read.
What price should I buy DGX at?
MELANY is not flagging a fresh entry for DGX at its current Hold rating, so there is no entry zone to publish right now. Watchlisting DGX in the free app gets you alerted the moment that changes.
What are the risks of buying DGX stock?
The top risks MELANY currently flags for Quest Diagnostics Inc.: Trading near 52-week high, limited upside without new positive catalyst. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Quest Diagnostics Inc. a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 50/100 for Quest Diagnostics Inc., and earnings track record, at 80/100. The 64/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will DGX stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 80/100 for DGX right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this DGX rating?
The rating on this page is a snapshot of MELANY's read as of 2026-08-24. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores DGX continuously as new price, earnings, and fundamental data arrive, and that current rating is free in the app.
DGX's live rating and alerts are free either way. The app is our flagship.